Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Astemizole is a second generation antihistamine, piperidine derivative without sedative or antimuscarinic action. It is indicated for the symptomatic relief of allergic rhinitis and conjunctivitis and urticaria. Oral administration once a day.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant amounts.
20% of infants (2 of 10) breast-fed by mothers taking astemizole had symptoms of irritability (Ito 1993).
It is a very long-lasting antihistamine because the half-life of its active metabolite is 10 to 20 days.
It has been withdrawn from the market in most countries due to the risk of adverse effects such as ventricular arrhythmia.